Psoriasis, cardiovascular syndrome and methotrexate
Year: 2016, volume 12 Issue: №3 Pages: 490-492
Heading: Dermatovenerology Article type: Author's opinion
Authors: Utz S.R., Juke A.N.
Organization: Saratov State Medical University
Heading: Dermatovenerology Article type: Author's opinion
Authors: Utz S.R., Juke A.N.
Organization: Saratov State Medical University
Summary:
Often while treating psoriasis, clinicians face great difficulty in choosing the best treatment for patient and often face the question such as: what preparation is more suitable in a concrete case? Especially in psoriasis associated with comorbid diseases. In this article the data from Russian and foreign literature is collected about the effectiveness of methotrexate (in small and medium doses) in treating not only psoriasis but also other comorbid diseases. The positive effects of this medication from cytostatic group having not only anti-tumor activity but also immunosuppressive effect are evident not only on underlying disease, but also on the associated disease that has similar pathogenesis.
Bibliography:
1.Dovzhansky SI, Utz SR. Psoriasis or psoriatic disease. Saratov: SGU, 1992
2.Bakulev AL, Stoda UM, Utz SR. On the question of comorbidity in psoriasis. Saratov Journal in Medical Scientific Research 2014; 10 (3): 537-539
3. Schon МР, Boehncke WH. Psoriasis. N Engl J Med 2005; 352(18): 1899-912
4. Shtoda UM, Slesarenko NA, Bakulev AL, Utz SR, Platonova AN. Endothelial dysfunction and its treatment in psoriasis patients 2015; (1): 62-66
5. Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep 2012; 14 (4): 343-8
6. Pieringer H, Pichler M, Pohanka E, et al. Will antirheumatic treatment improve cardiovascular outcomes in patients with rheumatoid arthritis? Curr Pharm Des2013 [Epub ahead of print]
7. Dowlatshahi EA, Kavousi M, Nijsten T, et al. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Investig Dermatol 2013; 133 (10): 2347-54
8. Utz SR. Current approaches to the treatment of psoriasis. Remedium Volga region 2016; 1 (141): 28-30
9. Ahlehoff О, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273 (2): 197-204
10. Nel'ubova Ol, Utz SR, Sazanova GYu, Morrison AV. Economical effectiveness of therapy in patients with psoriasis (review). Saratov Journal of Medical Scientific Research 2014; 10 (3): 508-511
11. Bili A, Tang X, Pranesh S, et al. TNF-a inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013 [Epub ahead of print]
12. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70 (4): 576-82
13. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy. Mediat Inflamm 2012; 2012: 674265
14. Bakulev AL Utz SR, Shtoda YM. Combined cytostatic and angioptotective therapy of psoriasis. Farmateka 2015; (1): 45-48
15. Popkova TV, Gerasimova EV, Novikova DC, Nasonov EL. Methotrexate and cardiovascular risk in rheumatoid arthritis. Scientific and Practical Rheumatology 2012: 6 (50)
16. Solomon DH, Curtis JR, Saag KG, et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-a blockade with nonbiologic DMARDs. Am J Med 2013; 126 (8): 730
17. Wakkee M, Meijer W, Neumann HA, et al. Psoriasis may not be an independent predictor for the use of cardiovascular and antidiabetic drugs: a 5-year prevalence study. Acta Derm Venereal 2009; 89 (5): 476-83
18. Slesarenko NA, Utz SR. The role of bacterial infection in the pathogenesis of psoriasis. Vestnik Dermatologii i Venerologii 2016; (3): 229-35
19. Morgan DR, Trimble М, McVeigh GE. Atrial fibrillation associated with sumatriptan. BMJ 2000; 321: 275
20. Hung MJ, Wang CH, Kuo LT, Cherng WJ. Coronary artery spasm-induced paroxysmal atrial fibrillation: a case report. Angiology 2001; 52: 559-62
21. Gu WJ, Weng CL, Zhao YT, et al. Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies. Int J Cardiol 2013; 168 (5): 4992-6.
| Attachment | Size |
|---|---|
| 2016_03-1_490-492.pdf | 233.39 KB |
Русский
English